Decreased MicroRNA Is Involved in the Vascular Remodeling Abnormalities in Chronic Kidney Disease (CKD)

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Chen, Neal X ^a   Kiattisunthorn, Kraiwiporn ^b   O'Neill, Kalisha D ^a   Chen, Xianming ^a   Moorthi, Ranjani N ^a   Gattone II, Vincent H ^a   Allen, Matthew R ^a   Moe, Sharon M ^a,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; MICRORNA; MICRORNA 125B; MICRORNA 145; MICRORNA 155; MYOCARDIN; TRANSCRIPTION FACTOR RUNX2;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CALCIFICATION; AORTA DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL FUNCTION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; EX VIVO STUDY; FEMALE; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GLOMERULUS FILTRATION; HEART VENTRICLE REMODELING; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; RUNX2 GENE; SMOOTH MUSCLE FIBER; THORACIC AORTA; VASCULAR SMOOTH MUSCLE CELL;

AGED; ANIMALS; BLOOD VESSELS; CASE-CONTROL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MICRORNAS; MIDDLE AGED; RATS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84878094151     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064558     Document Type: Article

References (50)

1. Bartel DP, (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
2. Xin M, Small EM, Sutherland LB, Qi X, McAnally J, et al. (2009) MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev 23: 2166-2178.
3. van Rooij E, Olson EN, (2007) MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 117: 2369-2376.
4. Lorenzen JM, Haller H, Thum T, (2011) MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nat Rev Nephrol 7: 286-294.
5. van Rooij E, (2012) Introduction to the series on microRNAs in the cardiovascular system. Circ Res 110: 481-482.
6. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105: 10513-10518.
7. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, et al. (2010) Circulating microRNAs in patients with coronary artery disease. Circ Res 107: 677-684.
8. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY, (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305.
9. K/DOQI (2004) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis (Suppl 1): 1-290.
10. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, et al. (2006) Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945-1953.
11. Block GA, Hulbert-Shearon TE, Levin NW, Port FK, (1998) Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. American Journal of Kidney Diseases 31: 607-617.
12. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, et al. (2005) Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520-528.
13. Pecoits-Filho R, Sylvestre LC, Stenvinkel P, (2005) Chronic kidney disease and inflammation in pediatric patients: from bench to playground. Pediatr Nephrol 20: 714-720.
14. Pisetkul C, Chanchairujira K, Chotipanvittayakul N, Ong-Ajyooth L, Chanchairujira T, (2010) Malnutrition-inflammation score associated with atherosclerosis, inflammation and short-term outcome in hemodialysis patients. J Med Assoc Thai 93Suppl 1: S147-156.
15. Boettger T, Beetz N, Kostin S, Schneider J, Kruger M, et al. (2009) Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest 119: 2634-2647.
16. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, et al. (2009) miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 460: 705-710.
17. Worm J, Stenvang J, Petri A, Frederiksen KS, Obad S, et al. (2009) Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp Beta and down-regulation of G-CSF. Nucleic Acids Res 37: 5784-5792.
18. Tili E, Croce CM, Michaille JJ, (2009) miR-155: on the crosstalk between inflammation and cancer. Int Rev Immunol 28: 264-284.
19. Faraoni I, Antonetti FR, Cardone J, Bonmassar E, (2009) miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta 1792: 497-505.
20. Martin MM, Lee EJ, Buckenberger JA, Schmittgen TD, Elton TS, (2006) MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J Biol Chem 281: 18277-18284.
21. Zheng L, Xu CC, Chen WD, Shen WL, Ruan CC, et al. (2010) MicroRNA-155 regulates angiotensin II type 1 receptor expression and phenotypic differentiation in vascular adventitial fibroblasts. Biochem Biophys Res Commun 400: 483-488.
22. Xu CC, Han WQ, Xiao B, Li NN, Zhu DL, et al. (2008) Differential expression of microRNAs in the aorta of spontaneously hypertensive rats. Sheng Li Xue Bao 60: 553-560.
23. Mizuno Y, Yagi K, Tokuzawa Y, Kanesaki-Yatsuka Y, Suda T, et al. (2008) miR-125b inhibits osteoblastic differentiation by down-regulation of cell proliferation. Biochem Biophys Res Commun 368: 267-272.
24. Goettsch C, Rauner M, Pacyna N, Hempel U, Bornstein SR, et al. (2011) miR-125b regulates calcification of vascular smooth muscle cells. Am J Pathol 179: 1594-1600.
25. Moe SM, Chen NX, Seifert MF, Sinders RM, Duan D, et al. (2009) A rat model of chronic kidney disease-mineral bone disorder. Kidney Int 75: 176-184.
26. Moe SM, Seifert MF, Chen NX, Sinders RM, Chen X, et al. (2009) R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD). Nephrol Dial Transplant.
27. Chen NX, O'Neill KD, Chen X, Kiattisunthorn K, Gattone VH, et al. (2011) Activation of arterial matrix metalloproteinases leads to vascular calcification in chronic kidney disease. Am J Nephrol 34: 211-219.
28. Cheng Y, Liu X, Yang J, Lin Y, Xu DZ, et al. (2009) MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res 105: 158-166.
29. Fasanaro P, D'Alessandra Y, Di Stefano V, Melchionna R, Romani S, et al. (2008) MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 283: 15878-15883.
30. Lorenzen JM, Kielstein JT, Hafer C, Gupta SK, Kumpers P, et al. (2011) Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol 6: 1540-1546.
31. Dai Y, Qiu Z, Diao Z, Shen L, Xue P, et al. (2012) MicroRNA-155 inhibits proliferation and migration of human extravillous trophoblast derived HTR-8/SVneo cells via down-regulating cyclin D1. Placenta 33: 824-829.
32. Cowley BD Jr, Gudapaty S, Kraybill AL, Barash BD, Harding MA, et al. (1993) Autosomal-dominant polycystic kidney disease in the rat. Kidney Int 43: 522-534.
33. Owens GK, Kumar MS, Wamhoff BR, (2004) Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 84: 767-801.
34. Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, et al. (2001) Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 89: 1147-1154.
35. Wenzel UO, Krebs C, Benndorf R, (2010) The angiotensin II type 2 receptor in renal disease. J Renin Angiotensin Aldosterone Syst 11: 37-41.
36. Wang Z, Wang DZ, Pipes GC, Olson EN, (2003) Myocardin is a master regulator of smooth muscle gene expression. Proc Natl Acad Sci U S A 100: 7129-7134.
37. Martin MM, Buckenberger JA, Jiang J, Malana GE, Nuovo GJ, et al. (2007) The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microrna-155 binding. J Biol Chem 282: 24262-24269.
38. Blanco RR, Austin H, Vest RN III, Valadri R, Li W, et al. (2012) Angiotensin Receptor Type 1 Single Nucleotide Polymorphism 1166A/C is Associated With Malignant Arrhythmias and Altered Circulating miR-155 Levels in Patients With Chronic Heart Failure. J Card Fail 18: 717-723.
39. Lim K, Lu TS, Molostvov G, Lee C, Lam FT, et al. (2012) Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 125: 2243-2255.
40. Suga T, Iso T, Shimizu T, Tanaka T, Yamagishi S, et al. (2011) Activation of receptor for advanced glycation end products induces osteogenic differentiation of vascular smooth muscle cells. J Atheroscler Thromb 18: 670-683.
41. Speer MY, Yang HY, Brabb T, Leaf E, Look A, et al. (2009) Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res 104: 733-741.
42. Speer MY, Li X, Hiremath PG, Giachelli CM, (2010) Runx2/Cbfa1, but not loss of myocardin, is required for smooth muscle cell lineage reprogramming toward osteochondrogenesis. J Cell Biochem 110: 935-947.
43. Chen NX, Moe SM, (2012) Vascular calcification: pathophysiology and risk factors. Curr Hypertens Rep 14: 228-237.
44. Chen NX, O'Neill KD, Duan D, Moe SM, (2002) Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 62: 1724-1731.
45. Moe SM, Duan D, Doehle BP, O'Neill KD, Chen NX, (2003) Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 63: 1003-1011.
46. Zhang Y, Xie RL, Croce CM, Stein JL, Lian JB, et al. (2011) A program of microRNAs controls osteogenic lineage progression by targeting transcription factor Runx2. Proc Natl Acad Sci U S A 108: 9863-9868.
47. Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D, et al. (2012) MicroRNAs miR-125a and miR-125b constitutively activate the NF-kappaB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci U S A 109: 7865-7870.
48. Jayawardena TM, Egemnazarov B, Finch EA, Zhang L, Payne JA, et al. (2012) MicroRNA-Mediated In Vitro and In Vivo Direct Reprogramming of Cardiac Fibroblasts to Cardiomyocytes. Circ Res 110: 1465-1473.
49. Emilian C, Goretti E, Prospert F, Pouthier D, Duhoux P, et al. (2012) MicroRNAs in patients on chronic hemodialysis (MINOS study). Clin J Am Soc Nephrol 7: 619-623.
50. Neal CS, Michael MZ, Pimlott LK, Yong TY, Li JY, et al. (2011) Circulating microRNA expression is reduced in chronic kidney disease. Nephrol Dial Transplant 26: 3794-3802.